Figure 3.

lnc-POP1-1 was regulated by VN1R5 to affect cisplatin resistance in HNSCC cells

(A) Cell viability was detected by CCK-8 assays when lnc-POP1-1 was knocked down in HN30 cells stably transfected with LV-VN1R5. The IC₅₀ values are shown on the right. (B) Cell viability was detected by CCK-8 assays when lnc-POP1-1 was overexpressed in KO-VN1R5 HN30/DDP cells. The IC₅₀ values are shown on the right. (C and D) Apoptosis was detected using flow cytometry in VN1R5-overexpressing HN4 and HN30 cells treated with 0 or 5 μM cisplatin after knockdown of lnc-POP1-1. (E) Under intraperitoneal injection with 5 mg/kg cisplatin every 3 days 5 times, the tumor volumes and weights of the mice subcutaneously inoculated with LV-VN1R5 HN30 cells treated with ASO-lnc-POP1-1/ASO-NC are shown (n = 6/group). (F) The tumor volumes of the four groups were calculated every 5 days. Cisplatin was injected intraperitoneally every 3 days 5 times. (G) Under intraperitoneal injection with 5 mg/kg cisplatin every 3 days 5 times, the tumor volume and weight from the mice subcutaneously inoculated with KO-VN1R5 HN30/DDP cells treated with LV-lnc-POP1-1 and LV-NC are shown (n = 6/group). (H) The tumor volumes of the four groups were calculated every 5 days. Cisplatin was injected intraperitoneally every 3 days 5 times. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001. Error bars, means ± SDs.